The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
about
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug WithdrawalMesalamine in the treatment and maintenance of remission of ulcerative colitisTherapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentrationPros and cons of medical management of ulcerative colitis.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis.Balsalazide disodium for the treatment of ulcerative colitis.Mesalazine-induced renal calculi.Efficacy and safety of drugs for ulcerative colitis.Drug-induced acute interstitial nephritis.Topical therapies in inflammatory bowel disease.Drug-induced nephropathies.3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.Mesalazine-induced multi-organ hypersensitivity.Once-daily mesalamine granules for ulcerative colitis.Mesalazine-induced myocarditis: a case report.
P2860
Q26777634-9AF9DD8A-8CE1-443A-871B-4351265DB5A3Q26801119-0C858C20-3A58-4CB1-A335-21BFE3D13FB1Q26865546-EE7F51B1-1684-4915-ADD7-71A214221B31Q34608415-A91DC84A-614B-4219-BEE0-7BFECFF09D49Q35100726-B4002852-00E0-464D-8DC8-2D6233AB49A7Q36144377-669B2427-D9F2-4219-BFE9-206E24F0D882Q36426949-24500461-EB62-4873-9B37-9976AD1DBF05Q37123430-FEBA4BE1-C15C-4D7E-BD80-6C4131B83DF9Q37143102-4C537929-BD01-4F2A-A72F-9AEB54033B6AQ37345858-B8ABE3F4-1303-4B7B-A9D0-5E0306DD5ADAQ37528584-852A6207-6CF8-44CB-8DE2-847BBAF37574Q37727232-ACDA896F-97A2-45D4-BB13-5D3154E16625Q37762154-52A4773F-7A3E-4742-A160-11FE90AA0695Q38050885-89C04B01-88B2-4A67-9C07-D5D2A9DF713BQ39037643-BF40B325-EC39-469A-84BF-A58E2BAC98F7Q39977343-E30C5701-3B10-40D9-BEBC-20521C6EC9B3Q40359623-D9FF3676-1478-4787-AF54-3CE58E2CFCB0Q42995730-FCED190B-14B4-46E3-9C17-3F80A7F8ABBCQ50284494-D58F7104-2417-4E78-99CB-AE4B338409FF
P2860
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
@ast
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
@en
type
label
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
@ast
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
@en
prefLabel
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
@ast
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
@en
P2860
P356
P1476
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
@en
P2093
Alan C Moss
Mark A Peppercorn
P2860
P304
P356
10.1517/14740338.6.2.99
P407
P577
2007-03-01T00:00:00Z